Business
Akoustis Reports First Quarter FY24 Results
Q1 Revenue Up 26% Year-Over-Year, In-Line with Prior Guidance Guiding Revenue Flat in December Quarter, then 18 to 25% Growth with Record Revenue Projected
About this update from Aktis Oncology, Inc.
Q1 Revenue Up 26% Year-Over-Year, In-Line with Prior Guidance Guiding Revenue Flat in December Quarter , then 18 to 25% Growth with Record Revenue Projected in March Quarter Growth, Cost Savings Initiatives, Chips ITC Refund Support Operating Cash Flow Breakeven
View stock analysis, news, and events for Aktis Oncology, Inc.